

- [4] Frohling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. *J Clin Oncol* 2005;23:6285–95.
- [5] Aaronson SA. Growth factors and cancer. *Science* 1991;254:1146–53.
- [6] Greenberger JS, Sakakeeny MA, Humphries RK, Eaves CJ, Eckner RJ. Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil/basophil) hematopoietic progenitor cell lines. *Proc Natl Acad Sci USA* 1983;80:2931–5.
- [7] Choi YL, Moriuchi R, Osawa M, Iwama A, Makishima H, Wada T, et al. Retroviral expression screening of oncogenes in natural killer cell leukemia. *Leuk Res* 2005;29:943–9.
- [8] Albritton LM, Tseng L, Scadden D, Cunningham JM. A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and confers susceptibility to virus infection. *Cell* 1989;57:659–66.
- [9] Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. *Proc Natl Acad Sci USA* 1993;90:8392–6.
- [10] Ohmine K, Ota J, Ueda M, Ueno S-I, Yoshida K, Yamashita Y, et al. Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells. *Oncogene* 2001;20:8249–57.
- [11] Onishi M, Kinoshita S, Morikawa Y, Shibuya A, Phillips J, Lanier LL, et al. Applications of retrovirus-mediated expression cloning. *Exp Hematol* 1996;24:324–9.
- [12] Mavilio F, Kreider BL, Valtieri M, Naso G, Shirsat N, Venturelli D, et al. Alteration of growth and differentiation factors response by Kirsten and Harvey sarcoma viruses in the IL-3-dependent murine hematopoietic cell line 32D C13(G). *Oncogene* 1989;4:301–8.
- [13] Rovera G, Valtieri M, Mavilio F, Reddy EP. Effect of Abelson murine leukemia virus on granulocytic differentiation and interleukin-3 dependence of a murine progenitor cell line. *Oncogene* 1987;1:29–35.
- [14] Witthuhn BA, Silvennoinen O, Miura O, Lai KS, Cwik C, Liu ET, et al. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. *Nature* 1994;370:153–7.
- [15] Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). *Nature* 1995;377:65–8.
- [16] Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. *J Biol Chem* 2002;277:47954–63.
- [17] Ihle JN, Nosaka T, Thierfelder W, Quelle FW, Shimoda K. Jaks and Stats in cytokine signaling. *Stem Cells* 1997;15(Suppl 1):105–11 [Discussion 12].
- [18] Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. *Cancer Cell* 2005;7:387–97.
- [19] Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. *Lancet* 2005;365:1054–61.
- [20] James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. *Nature* 2005;434:1144–8.
- [21] Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. *N Engl J Med* 2005;352:1779–90.
- [22] Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. *Mol Cell Biol* 2000;20:3387–95.
- [23] Argetsinger LS, Kouadio JL, Steen H, Stensballe A, Jensen ON, Carter-Su C. Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. *Mol Cell Biol* 2004;24:4955–67.

## Gene Expression Profiles of CD133-positive Fractions Predict the Survival of Individuals with Acute Myeloid Leukemia

YOSHIHIRO YAMASHITA<sup>1</sup>, JUN OHASHI<sup>2</sup>, YUJI HIRAI<sup>3</sup>, YOUNG LIM CHOI<sup>1</sup>, RURI KANEDA<sup>1</sup>, SHIN-ICHIRO FUJIWARA<sup>1,4</sup>, YUKIHIRO ARAI<sup>5</sup>, MIYUKI AKUTSU<sup>6</sup>, CHIZUKO TSUTSUMI<sup>7</sup>, YASUSHI MIYAZAKI<sup>7</sup>, KENSUKE USUKI<sup>8</sup>, MASANAO TERAMURA<sup>3</sup>, KINUKO MITANI<sup>5</sup>, YASUHIKO KANO<sup>6</sup>, MICHAEL C. O'NEILL<sup>9</sup>, AKIO URABE<sup>8</sup>, MASAO TOMONAGA<sup>7</sup>, KEIYA OZAWA<sup>4</sup> and HIROYUKI MANO<sup>1,10</sup>

Divisions of <sup>1</sup>Functional Genomics and <sup>4</sup>Hematology, Jichi Medical University, Tochigi 329-0498; <sup>2</sup>Department of Human Genetics, Graduate School of Medicine, University of Tokyo, Tokyo 113-0033; <sup>3</sup>Department of Hematology, Tokyo Women's Medical University, Tokyo 162-8666; <sup>5</sup>Department of Hematology, Dokkyo University School of Medicine, Tochigi 321-0293; <sup>6</sup>Tochigi Cancer Center, Tochigi 320-0834; <sup>7</sup>Department of Hematology and Molecular Medicine Unit, Nagasaki University, Nagasaki 852-8523; <sup>8</sup>Department of Hematology, Kanto Medical Center NTT EC, Tokyo 141-8625, Japan; <sup>9</sup>Department of Biological Sciences, University of Maryland, Baltimore, Maryland 21250, U.S.A.; <sup>10</sup>CREST, Japan Science and Technology Agency, Saitama 332-0012, Japan

**Abstract.** *Background:* The current classification of acute myeloid leukemia (AML) is based predominantly on the cytogenetic abnormalities and morphology of the malignant blasts and is not always helpful for optimization of the treatment strategy. Gene expression profiles of AML blasts were obtained and a gene expression-based means of predicting the outcome of AML patients was developed. *Materials and Methods:* CD133-positive hematopoietic stem cell-like fractions were purified from the bone marrow of 99 individuals with AML-related disorders and the expression profiles of ~33,000 human transcripts in these cells were characterized with the use of DNA microarray analysis. *Results:* The comparison of the expression data between individuals with short- or long-term survival by application of Cox's proportional hazard model led to the identification of four genes, whose expression patterns discriminated between the two groups. The gene expression-based stratification (GES) system, based on a combination of the karyotype approach and the risk index calculated from the expression levels of the four outcome predictor genes, was developed to separate the patients into subgroups with distinct prognoses. *Conclusion:* DNA microarray analysis of purified

fractions provides novel stratification schemes for AML based on the expression profiles of a handful of genes.

Acute myeloid leukemia (AML) is characterized by clonal growth of immature leukemic blasts in the bone marrow (BM). Although current chemotherapeutic regimens induce an initial complete remission in >70% of affected individuals, the long-term survival of such patients remains poor (5-year survival rate of <30%) (1). Given that leukemic blasts of individuals with AML differ in their abilities to differentiate into cells of the granulocyte, monocyte, erythrocyte, or megakaryocyte lineages, the French-American-British Cooperative Group (FAB) established a classification scheme for AML (M0 to M7) based on blast morphology and differentiation commitment (2). Although some FAB subtypes have proved to be related to good or poor prognosis, the clinical relevance of this classification scheme is complicated by other clinical parameters. A preceding history of myelodysplastic syndrome (MDS) or anticancer treatment, for example, is an important indicator of poor prognosis (3).

One of the most robust predictors of AML prognosis is the blast karyotype (1, 4). A good prognosis is thus predicted from the presence in leukemic clones of t(8;21), t(15;17), or inv(16) chromosomal rearrangements ("favorable" karyotype), whereas -7/7q-, 11q23, or more complex (affecting three or more chromosomes) abnormalities are indicative of a poor outcome ("adverse" karyotype). Other karyotypes are classified as "intermediate." The World Health Organization (WHO) has proposed a classification of AML that separates

*Correspondence to:* Hiroyuki Mano, Division of Functional Genomics, Jichi Medical School, 3311-1 Yakushiji, Kawachigun, Tochigi 329-0498, Japan. Tel: +81-285-58-7449, Fax: +81-285-44-7322, e-mail: hmano@jichi.ac.jp

*Key Words:* DNA microarray, prognosis prediction, gene expression profile.

individuals with cytogenetic (or molecular) evidence of t(8;21), t(15;17), inv(16)/t(16;16), or 11q23 abnormalities into distinct subcategories (5). However, this classification is of little help for predicting the prognosis of AML patients with a normal karyotype, who constitute ~50% of the AML population. Given that AML patients with a normal karyotype are considered to be at intermediate risk, the corresponding leukemic blasts may harbor heterogeneous minor genomic rearrangements or mutations.

DNA microarray analysis has the potential to provide a stratification scheme for AML based on gene expression profiles and is able to predict the prognosis of each affected individual (6). To facilitate the development of such a genomics approach to the classification of human leukemias, a large-scale cell bank (the Blast Bank) was set up for the storage of CD133 (AC133)-positive hematopoietic stem cell (HSC)-like fractions purified from individuals with a wide range of leukemic disorders (7, 8). CD133 is specifically expressed on HSCs and hemangioblasts that are CD34<sup>+</sup>CD38<sup>-</sup> (9, 10). There are at least two advantages to the use of such purified immature fractions for the characterization of AML. First, given that the proportion of leukemic blasts within BM varies substantially (20 to almost 100%) among patients and that leukemic blasts possess the ability to differentiate to various extents, a simple comparison of BM mononuclear cells (MNCs) among heterogeneous AML patients is likely to reveal a large number of changes in gene expression that reflect differences either in the percentage of blasts within BM, or in the differentiation ability of the blasts. Analysis of Blast Bank specimens should thus minimize such population-shift effects (7). Second, although leukemic cells in a given patient comprise a mixture of malignant clones at various levels of differentiation, they are thought to be generated from a small number of leukemic stem cells (LSCs), similar to the situation for normal hematopoiesis (11, 12). Characterization of the LSCs should provide insight into the molecular mechanisms of leukemogenesis. Given that such LSCs are exclusively CD34<sup>+</sup>CD38<sup>-</sup>, the Blast Bank may represent a diverse collection of LSC specimens. Cancer stem cells of malignant glioblastoma, but not their progenies, have also been shown to specifically express CD133 (13).

DNA microarray analysis was used here to characterize the expression profiles of ~44,000 probe sets in the CD133<sup>+</sup> fractions of 99 adults with AML-related disorders. Statistical analyses of the resulting large data set provided the basis for a new classification of AML that facilitates prediction of the long-term prognosis of affected individuals.

## Materials and Methods

*Purification of CD133<sup>+</sup> cells.* Informed consent was obtained from each of the study subjects and the study was approved by the appropriate institutional review boards. Table I shows the clinical

characteristics of the study subjects. MNCs were isolated by density gradient centrifugation from BM aspirates of each patient and were subjected to chromatography on a miniMACS column (Miltenyi Biotec, Auburn, CA, USA) with magnetic bead-conjugated monoclonal antibodies to CD133 (AC133 MicroBeads; Miltenyi Biotec) as described previously (7). In most instances, the CD34<sup>hi</sup>CD38<sup>lo</sup> fraction constituted >90% of the eluate of the affinity column, as judged by flow cytometry.

*Microarray analysis.* Total RNA was extracted from the CD133<sup>+</sup> cell preparations with the use of an RNeasy Mini column and RNase-free DNase (Qiagen, Valencia, CA, USA). It was then subjected to two rounds of amplification of mRNA with T7 RNA polymerase (14); the high fidelity of the amplification step has been demonstrated previously (15). The resulting cRNAs were labeled with biotin and subjected to hybridization with GeneChip HGU133 A&B microarrays with the GeneChip system (Affymetrix, Santa Clara, CA, USA). The fidelity of the microarray data was confirmed by quantitative RT-PCR analysis.

*Method for real-time RT-PCR.* Portions of non-amplified cDNA were subjected to-PCR with a QuantiTect SYBR Green PCR Kit (Qiagen). The amplification protocol comprised incubations at 94°C for 15 sec, 60°C for 30 sec and 72°C for 60 sec. Incorporation of the SYBR Green dye into the PCR products was monitored in real time with an ABI PRISM 7700 sequence detection system (PE Applied Biosystems, Foster City, CA, USA), thereby allowing determination of the threshold cycle ( $C_T$ ) at which exponential amplification of products begins. The  $C_T$  values for cDNAs corresponding to *GAPDH* and the target genes were used to calculate the abundance of target gene mRNA relative to that of *GAPDH* mRNA. The primer sequences used for RT-PCR were as follows:

### FGFR1:

Correlation coefficient between RT-PCR and microarray data=0.746.

Sense primer: 5'-CCACCAGAGTGATGTGTG  
GTCTTT-3'

Antisense primer: 5'-CATCATCATGTACAGCTC  
GTTGGT-3'

### NRLN1

Correlation coefficient between RT-PCR and microarray data=0.638.

Sense primer: 5'-AATAGACGGAAAATGCTGCA  
AGGT-3'

Antisense primer: 5'-TGAGGTGGTCTCTCAGTCTCC  
AGT-3'

### ZNF6

Correlation coefficient between RT-PCR and microarray data=0.779.

Sense primer: 5'-ATCTGGTGCAAAAACAGA  
AAGGTG-3'

Antisense primer: 5'-GGCGGGTTTATGCAGTATTT  
AACAG-3'

### SCGF

Correlation coefficient between RT-PCR and microarray data=0.715.

Sense primer: 5'-TACTACGTCTGCGAGTTC  
CCCTTC-3'

Antisense primer: 5'-GCCCTTCAAGGAAAGA  
CACTAAC-3'

HOXA9  
Correlation coefficient between RT-PCR and microarray data=0.586.  
Sense primer: 5'-CTCAGGTTGTTTATGAGG  
GGAAAA-3'  
Antisense primer: 5'-ATGAATCTATGCATCCCC  
GAGAAC-3'

ANGPT1  
Correlation coefficient between RT-PCR and microarray data=0.719.  
Sense primer: 5'-GGCTGGGGAATGAGTTT  
ATTTTTG-3'  
Antisense primer: 5'-AAATCAGCACCGTGTAAG  
ATCAGG-3'

241376\_at (EST)  
Correlation coefficient between RT-PCR and microarray data=0.672.  
Sense primer: 5'-CAACTCGAAGCTCAAA  
TACCCTCA-3'  
Antisense primer: 5'-ACCGTTTATACACCAACGG  
TCACA-3'

FLJ13063  
Correlation coefficient between RT-PCR and microarray data=0.502.  
Sense primer: 5'-AGAGTTCTGCTGTGT  
CCTCTG-3'  
Antisense primer: 5'-CAGGACAGTGCTGAAC  
CAATG-3'

TSPAN-2  
Correlation coefficient between RT-PCR and microarray data=0.479.  
Sense primer: 5'-GCAGTTGAAAATTGTG  
GGAAAGAG-3'  
Antisense primer: 5'-CCCACACACAACTAGGA  
GAAGATG-3'

KIAA0830  
Correlation coefficient between RT-PCR and microarray data=0.575.  
Sense primer: 5'-TCCAGAGGCATCTGAGG  
GAAGTAG-3'  
Antisense primer: 5'-ATGGCCATGAAGTATGA  
GATGGTG-3'

DJ79P11.1  
Correlation coefficient between RT-PCR and microarray data=0.625.  
Sense primer: 5'-CCATCCTGCAGTATAG  
ATGGGACA-3'  
Antisense primer: 5'-GATTCAGGGCATAAGGC  
AAAATC-3'

POU4F1  
Correlation coefficient between RT-PCR and microarray data=0.643.  
Sense primer: 5'-ATGAACAAGCCTGAGC  
TCTTCAAC-3'  
Antisense primer: 5'-GAGAATTTTCATCCGCT  
TCTGCTTC-3'

IGHM  
Correlation coefficient between RT-PCR and microarray data=0.593.  
Sense primer: 5'-CAGAAGAACATCGGAG  
ACCAGAGA-3'

Antisense primer: 5'-AACCAAGCGTATACACAG  
CAAAGCA-3'

GAPDH  
Sense primer: 5'-GTCAGTGGTGGACCT  
GACCT-3'  
Antisense primer: 5'-TGAGCTTGACAAAGTG  
GTCG-3'

*Statistical analysis.* The mean expression intensity of the internal positive control probe sets ([http://www.affymetrix.com/support/technical/mask\\_files.affx](http://www.affymetrix.com/support/technical/mask_files.affx)) was set to 500 units (U) in each hybridization and the fluorescence intensity of each test probe set was normalized accordingly. All normalized array data are available at the Gene Expression Omnibus web site (<http://www.ncbi.nlm.nih.gov/geo>) under the accession number GSE1427. All expression values were transformed to logarithms prior to statistical analyses. Hierarchical clustering of the data set and Student's *t*-test were performed with GeneSpring 7.0 software (Silicon Genetics, Redwood, CA, USA). Principal component analysis (16) and survival analyses were performed with the SAS software package (ver. 8.0.2).

## Results

*Purification of CD133<sup>+</sup> HSC-like fractions.* The number of CD133<sup>+</sup> cells isolated from BM MNCs varied markedly among FAB subtypes of AML. For individuals whose leukemic blasts had a low differentiation capacity (FAB subtypes M0 to M2), for example, the blasts purified by CD133-based affinity chromatography constituted  $\geq 30\%$  with MNCs. In contrast, the blasts purified from individuals with FAB subtypes M3 (characterized by prominent differentiation to the promyelocyte level) or M5 (differentiation to the promonocyte level) constituted  $< 1\%$  of MNCs. In both the latter instances, large promyelocytes (M3) or large promonocytes (M5) constituted a major proportion of the BM MNCs, whereas the corresponding column eluates contained only medium-sized, agranular blasts with a high nucleus-to-cytoplasm ratio (Figure 1A).

The affinity column thus appeared to select for a minor population of cells at a highly immature level of differentiation. To verify that such cells in the column eluates did indeed represent leukemic clones, fluorescence *in situ* hybridization analysis was performed with the cells purified from several individuals. In the case of FAB subtype M3, described above, a t(15;17) was detected in 75% of the purified blasts (data not shown). Similarly, in an AML case characterized by 5q- or a case of chronic myelogenous leukemia characterized by t(9;22), the corresponding abnormality was detected in  $>90$  or 70.7% (8) of cells in the column eluates, respectively. These findings indicate that most of the cells in the column eluates were malignant clones, especially given the only moderate sensitivity of fluorescence *in situ* hybridization.

*Gene expression profiles of the Blast Bank specimens.* All the specimens were collected from the patients before initiation of chemotherapy. The expression profiles of  $>44,000$  probe

Table I. Clinical characteristic of the study subjects.

Blast Bank ID	Age (yr)	Gender	Disease	FAB subtype	Karyotype	Blast Bank ID	Age (yr)	Gender	Disease	FAB subtype	Karyotype
ID020	66	Female	AML evolved from MDS	M2	Normal	ID276	64	Male	de novo AML	M2	-7, >3
ID023	34	Female	de novo AML	M6	Others>=3	ID277	23	Female	de novo AML	M4	inv16
ID026	46	Male	de novo AML	M3	Others≤2	ID278	16	Female	de novo AML	M4	Normal
ID027	49	Male	AML evolved from MDS	M2	Normal	ID279	68	Male	de novo AML	M2	t(8;21)
ID028	62	Male	AML evolved from MDS	M2	Normal	ID280	68	Male	de novo AML	M1	-7
ID032	75	Male	RAEB		Others>=3	ID288	61	Male	de novo AML	M5	Normal
ID035	61	Male	de novo AML	M2	Others≤2	ID292	74	Male	de novo AML	M6	Normal
ID036	74	Male	de novo AML	M0	Normal	ID305	63	Male	de novo AML	M2	Normal
ID042	67	Female	AML evolved from MDS	M2	Others>=3	ID306	43	Male	de novo AML	M1	Normal
ID045	69	Male	RAEB		+8	ID310	75	Male	de novo AML	M0	Normal
ID046	84	Male	de novo AML	M2	-7	ID313	88	Female	AML evolved from MDS	M1	Others>=3
ID051	42	Male	RAEB		Others>=3	ID314	55	Female	de novo AML	M5	+8
ID054	84	Male	AML evolved from MDS	M2	-7	ID315	45	Female	RAEB		Others>=3
ID062	72	Male	de novo AML	M0	Normal	ID316	30	Male	de novo AML	M1	Others>=3
ID063	67	Female	RAEB		Others>=3	ID317	36	Male	de novo AML	M2	t(8;21)
ID066	73	Male	RAEB		t(8;21)	ID318	53	Male	de novo AML	M2	Normal
ID076	37	Male	de novo AML	M2	t(8;21)	ID319	47	Male	de novo AML	M6	Others>=3
ID077	55	Male	RAEB		+8	ID321	68	Female	de novo AML	M2	t(8;21)
ID083	64	Female	de novo AML	M4	Normal	ID325	49	Male	de novo AML	M2	Others>=3
ID087	66	Male	de novo AML	M5	Normal	ID326	68		de novo AML	M1	Normal
ID093	53	Female	de novo AML	M5	Others≤2	ID329	79	Female	de novo AML	M2	Normal
ID098	66	Male	AML evolved from MDS	M0	Normal	ID338	57	Male	RAEB		Normal
ID104	72	Male	de novo AML	M0	Others>=3	ID339	72	Female	de novo AML	M4	inv16
ID107	48	Female	de novo AML	M5	Others≤2	ID347	52	Male	de novo AML	M2	Others≤2
ID109	86	Male	de novo AML	M1	Normal	ID349	70	Male	de novo AML	M6	Others>=3
ID127	41	Male	de novo AML	M2	Normal	ID355	69	Male	de novo AML	M2	t(8;21)
ID139	50	Male	de novo AML	M1	Others≤2	ID362	59	Female	de novo AML	M2	Normal
ID142	38	Male	de novo AML	M2	t(8;21)	ID363	67	Male	de novo AML	M0	Others>=3
ID148	74	Male	AML evolved from MDS	M2	Normal	ID375	32	Male	de novo AML	M2	Normal
ID154	49	Male	RAEB		Normal	ID376	23	Male	de novo AML	M0	Others≤2
ID174	51	Male	de novo AML	M0	Normal	ID378	28	Female	de novo AML	M2	t(8;21)
ID180	47	Male	de novo AML	M4	Normal	ID379	62	Male	de novo AML	M2	Normal
ID183	50	Female	de novo AML	M2	t(8;21)	ID380	51	Female	de novo AML	M6	Others>=3
ID188	59	Male	de novo AML	M2	t(8;21)	ID382	49	Female	AML evolved from MDS	M2	Others>=3
ID195	61	Female	de novo AML	M2	t(8;21)	ID385	79	Male	RAEB		Normal
ID205	39	Male	de novo AML	M1	Normal	ID388	45	Male	de novo AML	M5	inv16
ID215	52	Male	RAEB		Others>=3	ID395	80	Male	AML evolved from MDS	M0	Normal
ID226	52	Male	de novo AML	M2	t(8;21)	ID402	63	Male	de novo AML	M1	Others≤2
ID227	29	Male	de novo AML	M2	Normal	ID409	72	Female	de novo AML	M1	Others≤2
ID234	68	Male	RAEB		Others≤2	ID410	67	Female	RAEB		Normal
ID239	48	Male	de novo AML	M2	t(8;21)	ID413	61	Female	de novo AML	M2	Normal
ID243	54	Female	RAEB		Others>=3	ID414	61	Male	de novo AML	M0	Normal
ID262	70	Female	de novo AML	M2	Others≤2	ID415	85	Female	de novo AML	M2	Others>=3
ID265	65	Male	de novo AML	M7	Normal	ID416	42	Female	de novo AML	M2	Normal
ID266	38	Male	de novo AML	M4	Normal	ID418	57	Female	de novo AML	M2	Normal
ID267	80	Male	de novo AML	M2	Normal	ID421	81	Female	RAEB		Normal
ID269	32	Female	de novo AML	M4	Others≤2	ID427	62	Male	de novo AML	M5	Normal
ID270	46	Female	de novo AML	M1	Others≤2	ID430	66	Female	RAEB		Others≤2
ID272	57	Female	de novo AML	M4	+8						
ID274	67	Male	de novo AML	M1	-7						
ID275	70	Male	AML evolved from MDS	M2	Others>=3						

AML=acute myeloid leukemia; MDS=myelodysplastic syndrome; FAB=French-American-British Cooperative Group; RAEB=refractory anemia with excess of blasts.

sets (corresponding to ~33,000 human genes) were then determined for Blast Bank specimens derived from 83 individuals with AML and 16 individuals in the advanced stage [refractory anemia with excess of blasts (RAEB)] of MDS. The clinical characteristics of the study subjects are provided in Table I.

For analysis of the expression data, the criterion that the expression level of a given probe set should receive the "Present" call (from Microarray Suite 5.0 software) in at least 30% ( $n=30$ ) of the samples was applied in order to exclude transcriptionally-silent genes from the analysis. A total of 11,595 probe sets passed this selection window. Unsupervised two-way hierarchical clustering analysis (17) was then applied to the 99 patients based on the expression profiles of these 11,595 probe sets, generating a dendrogram of the subjects (Figure 1B). Six out of the 16 patients with RAEB (MDS) clustered together in the dendrogram, whereas the remaining ten RAEB patients were intermixed with the AML cases. Given that eleven of our AML subjects had experienced a previous MDS phase, it was not surprising that the gene expression profiles did not clearly separate RAEB from heterogeneous AML.

Patients with a normal karyotype or "other" abnormalities ( $<3$  or  $\geq 3$ ) were widely distributed throughout the dendrogram, indicative of the highly heterogeneous character of their blasts. Previous unsupervised clustering analysis of the gene expression profiles of BM MNCs from individuals with AML separated the patients into subgroups that were strongly related to the FAB subtype (18, 19). However, such a relationship was not apparent in our analysis of CD133<sup>+</sup> cells (data not shown), suggesting that changes in gene expression that accompany the differentiation of leukemic blasts within BM might greatly influence the overall gene expression profiles of MNCs.

*Gene expression profiles linked to good prognosis.* Among the 83 AML patients studied, 66 individuals were treated with standard chemotherapeutic regimens according to the protocols of the Japan Adult Leukaemia Study Group (JALSG). Kaplan-Meier analysis of these 66 cases revealed that, although the prognosis of individuals with the adverse karyotype was significantly worse than that of the other two karyotype groups (long-rank test,  $p<0.001$ ), the prognosis of patients with the favorable karyotype did not differ from that of those with the intermediate one ( $p=0.06$ ) (Figure 2). The poor prognosis of individuals with the adverse karyotype (5-year survival rate of ~10%) has been confirmed extensively (1, 4, 20), but the intermediate group apparently contains both patients with a curable disorder and those with an intractable one. It is, therefore, of clinical importance to be able to identify individuals with a *bona fide* good prognosis from among those with a favorable or intermediate karyotype.

We next compared the transcriptomes of individuals with these two karyotype designations. Among the 66 AML patients who underwent standard chemotherapy, the blasts of 16 and 39 individuals had the favorable and intermediate karyotypes, respectively. Probe sets that received the "Present" call in  $\geq 10\%$  ( $n=6$ ) of these 55 cases were selected first. The selected 17,724 probe sets were then screened for those whose expression differed significantly between the two karyotype groups (Student's *t*-test,  $p<0.001$ ), resulting in the identification of 378 such sets. Application of principal component analysis reduced the number of principal gene expression patterns from 378 to three. On the basis of the calculated coordinates of these three principal expression patterns, the 55 samples were projected into a virtual three-dimensional space (Figure 3A). The samples with favorable and intermediate karyotypes were not clearly separated from each other, however.

We, therefore, examined whether it was possible to identify a gene expression profile, or "molecular signature," that was directly linked to the prognosis of leukemic patients. Among the 55 patients with favorable or intermediate karyotypes who underwent standard chemotherapy, 14 individuals survived for  $\geq 755$  days (long-term survivors) and eight individuals died within 365 days (short-term survivors) after the first chemotherapy. The application of the Student's *t*-test to the gene expression data for these 22 cases identified five probe sets, the expression level of which contrasted the two groups ( $p<0.001$ ) (Table II). Principal component analysis and three-dimensional projection indicated that the molecular signature was clearly different between the two patient classes (Figure 3B).

*Gene expression-based stratification scheme for AML.* We next attempted to develop a gene expression-based stratification (GES) system for AML. Given that the adverse karyotype is a reliable indicator of poor prognosis, we tried to construct a GES scheme to isolate those individuals with good prognosis from other patients. The 66 AML patients who underwent standard chemotherapy were divided into training ( $n=44$ ) and test ( $n=22$ ) sets (Figure 4A). The former contained 37 patients with favorable or intermediate karyotypes, seven and six of whom were long-term or short-term survivors, respectively. To identify a prognosis-related molecular signature, the Student's *t*-test was first applied to the expression data for these latter 13 cases to isolate probe sets whose expression differed significantly ( $p<0.01$ ) between the two groups. The expression profiles of the resulting 38 probe sets were then subjected to Cox's proportional-hazard regression analysis (21) ( $p<0.01$ ) for the 13 selected individuals. Four independent probe sets (outcome predictor genes) were finally isolated, the expression profiles of which are shown in a dendrogram in Figure 3B. The risk index (RI)




Figure 1. Clustering analysis of purified CD133<sup>+</sup> fractions from individuals with acute myeloid leukemia (AML)-related disorders. A) The CD133<sup>+</sup> fractions (right panels) were purified from bone marrow mononuclear cells (MNCs) (left panels) of AML patients of FAB subtypes M3 (upper panels) or M5 (lower panels). The cells were stained with Wright-Giemsa solution. Scale bar, 10  $\mu$ m. B) Unsupervised clustering of the study subjects based on the similarity in expression profiles of 11,595 probe sets. The karyotype of each patient is colored differentially. Individuals with refractory anemia with excess blasts are indicated by dots.

(22) was calculated for each patient based on the expression intensity and the parameter estimate (Table III) for each of these four probe sets.

A GES system for AML, based on a combination of this RI-based classification scheme and the karyotype-based scheme, is thus proposed (Figure 5A). AML patients with an adverse karyotype are classified as GES class III, whereas the other patients are classified as either GES class I (RI < -9.36) or GES class II (RI  $\geq$  -9.36) on the basis of the calculated RI for the four outcome predictor genes. To examine whether the GES system is able to select patients with good prognosis, Kaplan-Meier analysis was performed with the 44 individuals in the training set classified according either to the karyotype-based scheme (Figure 5B) or to our GES scheme (Figure 5C). The prognosis of the favorable group of the karyotype-based classification did not




Figure 2. Long-term survival according to the keryotype-based stratification of the 66 acute myeloid leukemia patients treated with standard chemotherapy.




Figure 3. Comparison of gene expression profiles by principal component analysis. A) Three principal components were derived from the gene expression patterns of 378 probe sets that contrasted acute myeloid leukemia (AML) patients with favorable or intermediate karyotypes who underwent standard chemotherapy. Samples were projected into a virtual space based on the coordinates of the three components. B) Sample projection was similarly performed for five probe sets that contrasted the long-term and short-term survivors among the patients in A.




Figure 4. Isolation of probe sets linked to survival time. A) Approach adopted to identify four probe sets whose expression contrasted the long-term and short-term survivors in a training set of acute myeloid leukemia (AML) patients. The numbers in parentheses indicate the corresponding numbers of subjects. RAEB; refractory anemia with excess of blasts. B) Gene tree for the expression levels (color coded as indicated by the scale at the bottom) of the four human genes identified in A for CD133<sup>+</sup> cells derived from seven long-term and six short-term survivors. Each row corresponds to a single gene (symbol shown at right) and each column to a different patient (Blast Bank ID shown at top).

differ significantly (log-rank test,  $p=0.10$ ) from that of the intermediate group. In contrast, the GES system clearly separated the patients into three groups with distinct prognoses. Importantly, only GES class I contained the long-term survivors.

The efficacy of the GES system was then examined with the 22 individuals in the test set, who were also classified by either the karyotype-based (Figure 5D) or GES (Figure 5E) schemes. Again the former scheme failed to separate the patients into prognosis-related



Table II. Expression intensities of five probe sets linked to survival of 14 long-term and eight short-term survivors of acute myeloid leukemia.

Affymetrix designation	Gene symbol	GenBank accession no.	Long-term survivors													
			ID026	ID035	ID087	ID093	ID139	ID142	ID174	ID195	ID226	ID227	ID239	ID266	ID269	ID270
217147_s_at	TRIM	AJ240085	22.2	22.4	5.3	42.9	26.5	4.9	0.9	3.6	14.2	6.4	43.0	11.0	30.5	27.9
203098_at	CDYL	AL050164	6.9	15.5	8.4	18.8	49.9	10.2	20.5	6.0	42.5	11.7	60.8	20.3	23.5	30.8
226333_at	IL6R	AV700030	16.3	34.0	68.4	39.2	20.2	52.3	60.5	80.3	54.2	60.6	49.4	107.4	50.6	24.4
243023_at		N34402	1.7	10.2	6.9	4.5	31.3	20.8	16.7	7.1	2.0	8.7	2.9	3.0	29.3	2.4
200663_at	CD63	NM_001780	170.0	73.0	132.4	181.5	74.4	97.7	60.4	94.2	112.9	112.8	102.1	68.2	82.0	76.6

Affymetrix designation	Gene symbol	GenBank accession no.	Short-term survivors							
			ID027	ID062	ID083	ID127	ID180	ID188	ID288	ID317
217147_s_at	TRIM	AJ240085	1.3	7.3	1.1	2.9	2.7	5.0	1.5	4.1
203098_at	CDYL	AL050164	48.5	60.1	35.1	30.7	44.3	67.4	33.2	47.0
226333_at	IL6R	AV700030	177.2	146.2	127.5	72.5	120.7	85.7	61.8	70.1
243023_at		N34402	28.8	33.5	33.4	23.4	24.5	10.8	19.7	19.5
200663_at	CD63	NM_001780	57.9	65.9	67.7	52.7	61.8	49.4	62.5	76.6

groups. In contrast, the GES scheme efficiently isolated the long-term survivors.

**Discussion**

In the present study, we attempted to develop a new classification scheme for AML based on the gene expression profiles of purified highly immature leukemic cells. Microarray analysis has proved effective for the prediction of prognosis in other hematological malignancies including diffuse large B cell lymphoma (DLBCL) (23-25) and acute lymphoblastic leukemia (ALL) (26, 27). The clinical specimens for these latter two disorders, however, appear to be more homogeneous than are those for AML. Lymphoma clones constitute most of the cell population within the affected lymph nodes of individuals with DLBCL and most ALL clones remain at an early precursor stage of the B or T cell lineage. The clinical specimens derived from individuals with DLBCL or ALL are thus probably representative of the corresponding malignant clones.

Caution is warranted, however, in the interpretation of microarray data for certain blood cell disorders. In Hodgkin's lymphoma, for example, the malignant cells constitute only a small proportion of cells within lymph nodes, most of which are inflammatory cells and normal lymphocytes. Hodgkin's lymphoma cells have thus been isolated with the use of laser-capture microdissection before microarray analysis (28, 29). Similar caution is required with AML, given the heterogeneity in both the proportion and differentiation ability of the blasts within BM. Indeed, our data indicated that so-called "leukemic blasts" are highly heterogeneous with regard to their differentiation ability, even within the BM of a single patient (Figure 1A), consistent with the notion of the presence of multiple types of LSC (12).

In the present study, statistical analysis of the gene expression profiles of CD133<sup>+</sup> HSC-like fractions resulted in the isolation of a very small number of outcome-predictor genes, including those for G protein-coupled receptor 56 (GPR56; GenBank accession number, NM\_005682), ring finger protein 146 (RNF146; NM\_030963), mitochondrial ribosomal protein S14 (MRPS14; NM\_022100) and T cell receptor-interacting protein (TCRIM; NM\_016388). Their predicted amino acid sequences indicate that GPR56 belongs to the family of cell surface proteins with seven transmembrane domains and that RNF146 participates in protein ubiquitination. MRPS14 is a component of the 28S subunit of mitochondrial ribosomes and contributes to protein synthesis in this organelle (30). TCRIM is a transmembrane protein that undergoes phosphorylation by Src family kinases (31). TCRIM potentially functions as a scaffold protein that recruits a variety of signaling proteins via its Src homology 2 (SH2) domain.

Table III. The outcome predictor genes for acute myeloid leukemia (AML).

Affymetrix designation	Gene symbol	GenBank accession no.	Parameter estimate	P value
203801_at	MRPS14	NM_022100	-2.30663	0.003
212070_at	GPR56	NM_005682	0.69679	0.0045
217147_s_at	TCRIM	NM_016388	-0.79050	0.0041
244517_x_at	RNF146	NM_030963	-0.97626	0.0018




Figure 5. The gene expression-based stratification (GES) system for acute myeloid leukemia (AML). A) Flow chart for GES classification of AML patients. B–E) Kaplan-Meier analysis of the 44 AML patients in the training set (B, C) and the 22 patients in the test set (D, E) classified according to karyotype-based stratification (B, D) or to the GES system (C, E).

Table IV. Expression intensities of 23 probe sets linked to prognosis in the acute myeloid leukemia patients treated with standard chemotherapy.

Affymetrix designation	Gene symbol	Genbank accession no.	Good prognosis																						
			ID026	ID035	ID076	ID087	ID093	ID107	ID139	ID142	ID174	ID183	ID195	ID226	ID227	ID239	ID265	ID266	ID269	ID270	ID277	ID278	ID279	ID314	
37384_at	PPM1F	DI3640	180.9	301.1	129.8	254.6	304.9	210.7	163.2	158.4	171.1	46	448.7	177.6	251.7	129.5	107.4	230.3	136.7	112.9	90	333.5	130	111.8	
243579_at	MSI2	BF029215	84.5	40	21.9	170.4	39.7	32.3	30.3	11.4	59	21.3	97.1	47.5	62.5	42.8	35.3	72.5	18	12.5	15.9	208.2	20.2	47.2	
228988_at	ZNF6	AUI57017	10.6	16.2	7.7	28.8	55.5	57.2	2.4	4.9	138.3	5.5	8.7	20.3	22.1	18.2	4.9	25.2	4.5	1.9	5	57.7	4.6	5.8	
228708_at		BF438386	23.2	10.5	54.5	44.7	16.6	20.1	39.6	10	38.8	57.9	12.9	22.5	59.2	97.7	89.4	49.8	60.7	63.3	112.4	171	32	3.2	
225651_at	FLI25157	BF431962	79.7	167	135	64.5	83.6	44.7	89.7	99.1	20.4	83.2	71.9	113	48.7	143	416.2	50.3	79.3	85.5	69.3	22.9	187.2	21.6	
225351_at	HT011	AK027029	66.1	62.1	174.7	67.1	73.4	42.2	90.6	193.2	40.5	183.6	164.2	311.1	46.8	407.5	494.6	42.3	302	31	87.2	47	163.3	32.3	
224516_s_at	HSPC195	BC006428	52.5	212.2	30.4	115.7	78.7	46.4	197.1	97.5	134	123	164.3	145	115.7	271.1	59.6	150.2	84.2	137.1	295.4	275	123.7	32.4	
224367_at	DJ79P11.1	AF251053	68.5	44.3	9.2	18.1	29.4	158.7	5.8	9.9	188.8	26.4	15.8	27.7	12.4	10.8	37.9	97	4.6	7.2	14.4	177.4	5.4	14.2	
219498_s_at	BCL11A	NM_1186	55.2	62.4	110.5	26.9	44	51	75.5	35.5	118.9	123.4	51.9	70.1	45.1	100.5	296.5	63.9	58.4	27.2	84.4	98.8	31.1	18.5	
217975_at	LOC51186	NM_016303	58.4	32.6	6.1	3.3	27.9	40.9	5.5	16.1	54.4	20.9	22.5	18.9	31.2	6.7	244	55.5	7.3	6.6	9.7	208.2	6.5	86.9	
215111_s_at	TSC22	AK027071	76.5	64	112.5	66.7	241.3	99.9	120.1	37.5	268.1	64.2	83.9	254.7	112.2	288	533.7	103.7	144.7	89.9	573.8	294.8	115.1	3.8	
214651_s_at	HOXA9	U41813	14.7	14.6	7.5	55.6	185.4	163.1	7.8	11.9	134.3	3	4.4	19.2	61	8.1	190.7	114.6	0.6	2.3	118.6	401.7	0.9	19.9	
212827_at	IGHM	X17115	753.6	151.3	35.5	222.3	136.6	142.3	47.2	57.6	214	36.7	62.8	23.8	138.8	24.8	69.9	49.1	21.6	20.8	205.3	185.4	55.4	48.7	
211709_s_at	SCGF	BC005810	300	683.9	1184.4	268.5	552.3	3194.6	365.7	2041.3	245.1	2181.9	2493.3	2796.9	315.3	2800.3	373.8	432	788.9	517.7	643.6	2391.3	1150.7	4488.4	
211341_at	POU4F1	L20433	59.6	612.2	233.8	28.9	16.6	5.5	29.9	813	11.4	607.5	1075	560.6	41	418.5	13.7	5.1	143	112.2	15.6	20.4	179.4	34.2	
209905_at	HOXA9	AI246769	72.8	5.2	1.3	19	15.5	306.4	1.3	3.4	139.6	4.8	6	2.8	85.1	1.6	204.2	193.6	0.9	0.5	198.4	797.2	0.9	40	
206478_at	KIAA0125	NM_014792	19	21.7	12.1	45.9	34	10.5	41.1	34.5	303.6	28.1	26.1	35.4	42.8	16.2	146.4	42	38.7	67.3	97.1	144.4	5.9	8.6	
205609_at	ANGPT1	NM_001146	50	807.3	22.7	43.4	66.3	70.9	354.2	19.8	130.9	41.4	104.4	21.6	277.3	25.5	82.1	637.4	18	347.6	688.9	357	47	2.5	
205608_s_at	ANGPT1	U83508	54.9	141.2	19.7	135.2	86.1	30.3	116.7	101.4	56.7	50.8	107.7	100	198.4	27.3	55.8	228.8	9	65.2	92.2	349.1	18	94.7	
204949_at	ICAM3	NM_002162	36.9	49.7	84.3	65.1	52.5	27.9	163.9	24.3	369.8	58.3	70.8	135.4	82.2	98.6	51.4	158.3	159.5	181	186.2	341.7	169.1	34.7	
204000_at	GNB5	NM_016194	11.9	37.8	13.6	19.8	63.7	9.9	87	19.3	27.1	31.6	41	39.6	21	2.7	25.1	7.4	62.9	55.1	29.4	69.4	9.3	82.6	
203063_at	PPM1F	NM_014634	107.6	147.5	127.5	151.8	164.8	129.1	138.7	186.2	173.1	120	190.3	225.1	233.4	86.3	56.2	167.8	117.3	97.1	78.4	239	65.7	86.2	
201315_x_at	IFITM2	NM_006435	217.8	156.4	339.9	286.1	437.7	201.2	55.2	64.7	268.1	67.3	139.9	218.8	132.7	279.4	41.7	121	84.5	93.9	49.3	148.2	320.1	134.4	

continued

Table IV. *continued*

Affymetrix designation	Gene symbol	Genbank accession no.	Poor prognosis																						
			ID0027	ID0042	ID054	ID062	ID083	ID127	ID188	ID288	ID313	ID317	ID325	ID349	ID380	ID388	ID402	ID409	ID413	ID414	ID415	ID416	ID418	ID427	
37384_at	PPM1F	D13640	222.4	415.7	235.3	199.8	165.9	204	275.8	274.9	339.4	394.5	518.6	281.9	268.6	317.5	160.1	444	240.2	134.5	193	180	276.7	191.9	
243579_at	MSI2	BF029215	38.5	118.9	62.3	90.9	19.5	49.2	156.3	293.6	80.7	17.3	41.5	159.3	222.8	70.7	44.5	168.9	34.9	123.8	125.1	170.6	456.3	100	
228988_at	ZNF6	AU157017	148.9	141.8	199	11.7	17.6	116.9	15.8	218.3	55.8	12.5	26.6	300.3	68	25.9	3.2	267.4	5.5	139	286.9	60	18.8	41.4	
228708_at	BF438386		127.2	196.3	430.7	37.8	58.7	137.7	137	118.6	66.2	57.7	44.8	82.6	28	99.3	18.5	358.5	12.5	117.1	18.4	149.4	33.4	129.7	
225651_at	FLJ25157	BF431962	62.9	47.7	11.8	86	18.7	60.5	26.1	19.1	56.5	93.7	23.8	39	97.8	92.2	30.4	56.7	45.7	33.7	54.7	25.9	88.7	74.8	
225351_at	HT011	AK027029	64.6	55.2	26.1	122.5	48	61.5	106.2	21	93.5	91.7	46.7	22.8	68.6	96.5	58	74.6	27	43.8	63.6	20.7	28	72.6	
224516_s_at	HSPC195	BC006428	295.5	158.1	466.3	174.2	208.9	241.3	62.4	199.8	168.4	131.8	107	127.4	223	387.3	138.4	166.9	110.7	165.6	172.2	175.6	207.8	146.2	
224367_at	DJ79P11.1	AF251053	188.6	343.3	173.7	8.1	93.5	345	56.7	202.8	45.3	5	24	475.1	307.3	38.6	3.5	363.7	12	259.9	273.9	136.9	109.7	68.8	
219498_s_at	BCL11A	NM_018014	106.4	233.2	108.4	237.3	135.8	66.6	90.8	80.4	182.9	83.7	54.5	169	101.5	238.5	71.7	229.2	66.3	155.1	114.6	87.3	201.6	54.2	
217975_at	LOC51186	NM_016303	208	191.6	111.8	10.1	64.9	157.5	6.5	88.4	303.8	5.9	36.8	350	173.9	124.6	7.7	75.5	38.8	163.6	291	102.1	227.1	160.1	
215111_s_at	TSC22	AK027071	366.5	709.6	696.9	562.8	281.6	255.7	143.3	198.4	282.8	115.8	114.9	904	195.1	669.3	50.8	316.5	68.2	233.1	289	143.8	258.5	215.9	
214651_s_at	HOXA9	U41813	293.6	379.5	166.6	125.8	121.9	121.7	34.3	326.8	180.5	14.7	247.4	231.1	158.6	157.3	1.6	389	4.9	159.5	215.6	108.1	65.5	324	
212827_at	IGHM	X17115	179.6	337.3	272	278.3	204.9	128.4	40.8	303.7	200.1	25.7	609.8	371.1	1002.5	471.9	19.6	120.2	62.4	393	224.2	456.1	124.2	295.4	
211709_s_at	SCGF	BC005810	91.2	459.8	47.1	857.1	494	313.7	1762.7	298.9	1004.1	899.4	19.2	225.2	796.7	2637.8	66.2	361.6	866.5	90.2	69	453.1	183.7	679.3	
211341_at	POU4F1	L20433	2	1.8	0.8	12.3	4	7.2	1089.2	9.8	22.5	790.7	12	16.3	7.5	49.2	39.3	95.6	2.5	13.1	13.4	17.5	21.3	55.8	
209905_at	HOXA9	AI246769	428	382.5	253.7	99.4	152.4	148.7	9.2	125.7	282.8	9.6	77.4	502.6	129.7	96.6	1.4	356.1	0.7	262.6	415.7	202.3	121.2	477.9	
206478_at	KIAA0125	NM_014792	517.3	198.9	584.7	127.7	317.1	39.8	27.4	31.2	94.3	43.3	39.7	185.6	90.9	84.5	33.7	144.8	16.7	99.1	79.5	49.5	40.1	105.4	
205609_at	ANGPT1	NM_001146	1554.3	1007.2	524.9	27.5	264.3	847.5	16.3	308.5	651.8	93.5	8.7	223.6	882.5	1067.1	306.5	362.8	123.5	261	606.1	236.6	988.8	317.3	
205608_s_at	ANGPT1	U83508	158.9	253.2	218.4	84.6	131.4	28.4	38	447.3	157.9	95.5	116.6	143.1	616	304.3	107.5	328.3	52.9	141	265.2	247.5	269	415.4	
204949_at	ICAM3	NM_002162	104.8	209.3	156.5	119.2	271.2	316.1	38.4	217.9	358.6	109.4	136.5	382.6	487.1	305.4	265.4	291.4	233.4	245	245.5	118.9	44.7	295.6	
204000_at	GNB5	NM_016194	15.4	91.7	57.4	26.4	58.7	140.5	36.3	40.6	83.2	90.9	61.7	48.3	35.6	129.1	30	20	151.1	33.3	76.8	75.7	654.9	119.8	
203063_at	PPM1F	NM_014634	187.6	318.6	216.8	132.2	166.5	126.5	189.9	278.2	263.3	128.3	439.2	240.2	163	280.5	131.1	265.3	175.6	129.1	144.6	152.2	142.9	246.5	
201315_x_at	IFITM2	NM_006435	274.8	291.4	464.2	492.5	374.1	390.3	127.1	115.3	299.1	245.8	670	379.9	176.6	337	219.7	177	235.3	158.9	187.5	68.6	185.7	170.9	

ANOVA ( $p < 0.01$ ) and effect size selection ( $\geq 50$  U) identified 31 probe sets: expression of which differed between individuals who failed to enter initial complete remission after the standard chemotherapy (poor prognosis) and those who remained at complete remission for  $> 1$  year after the standard chemotherapy (good prognosis). The Cox proportional hazard model was applied to such probe sets to isolate 23 probe sets whose expression levels correlated ( $p < 0.05$ ) with survival time. The expression intensities of these 23 probe sets are shown.

Recent microarray analyses of BM MNCs from AML patients identified a cluster of ~100 genes whose expression patterns discriminated among AML subtypes (19) and 133 genes whose expression patterns were predictive of clinical outcome (32). Both *GPR56* and *TCRIM* were among the former group of genes.

Given that our data set was obtained with purified HSC-like fractions, it should prove informative with regard to characterization, through various approaches, of undifferentiated leukemic clones (probably including LSCs). For example, comparison between the individuals with good and poor prognosis among the 66 AML patients who underwent standard chemotherapy revealed preferential expression of *ANGPT1* in the latter group (Table IV); this gene encodes an angiogenic factor (angiopoietin 1) and is frequently overexpressed in a wide variety of human cancers (33, 34). An increased level of expression of *TEK*, which encodes a receptor for ANGPT1, was also detected in the blasts of ~10% of all 99 study subjects, some of whom overexpressed both *TEK* and *ANGPT1* (data not shown). These data suggest that an autocrine loop consisting of ANGPT1 and TEK might contribute to the malignant transformation in AML.

In contrast to the requirement for quantitation of the expression of >100 genes in the previously described approaches to prognosis prediction with BM MNCs from AML patients (19, 32), our GES system relies on determination of the expression levels of only four genes. Analysis of such a small number of genes is within the scope of an assay based on simple methodology, such as multiplex PCR. Although the GES system requires purification of CD133<sup>+</sup> cells, a combination of karyotyping and multiplex PCR is relatively straightforward even in current clinical settings. A large prospective study is now needed to verify whether individuals with AML of GES class I should be treated by standard chemotherapies, and those with AML of GES class II or III should receive more aggressive treatments such as BM transplantation.

### Acknowledgements

We thank P. Simon for helpful discussion and suggestions. This work was supported, in part, by grants for Research on Human Genome and Tissue Engineering and for Third-Term Comprehensive Control Research for Cancer from the Ministry of Health, Labor, and Welfare of Japan, as well as by a grant for Scientific Research on Priority Areas "Applied Genomics" from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

### References

- 1 Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA and Bloomfield CD: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with *de novo* acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). *Blood* 100: 4325-4336, 2002.
- 2 Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. *Ann Intern Med* 103: 620-625, 1985.
- 3 Goasguen JE, Matsuo T, Cox C and Bennett JM: Evaluation of the dysmyelopoiesis in 336 patients with *de novo* acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival. *Leukemia* 6: 520-525, 1992.
- 4 Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A and Goldstone A: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. *Blood* 92: 2322-2333, 1998.
- 5 Jaffe ES, Harris NL, Stein H and Vardiman JW: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001.
- 6 Liu ET and Karuturi KR: Microarrays and clinical investigations. *N Engl J Med* 350: 1595-1597, 2004.
- 7 Miyazato A, Ueno S, Ohmine K, Ueda M, Yoshida K, Yamashita Y, Kaneko T, Mori M, Kirito K, Tushima M, Nakamura Y, Saito K, Kano Y, Furusawa S, Ozawa K and Mano H: Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. *Blood* 98: 422-427, 2001.
- 8 Ohmine K, Ota J, Ueda M, Ueno S-i, Yoshida K, Yamashita Y, Kirito K, Imagawa S, Nakamura Y, Saito K, Akutsu M, Mitani K, Kano Y, Komatsu N, Ozawa K and Mano H: Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells. *Oncogene* 20: 8249-8257, 2001.
- 9 Hin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J and Buck DW: AC133, a novel marker for human hematopoietic stem and progenitor cells. *Blood* 90: 5002-5012, 1997.
- 10 Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA and Rafii S: Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. *Blood* 95: 952-958, 2000.
- 11 Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nat Med* 3: 730-737, 1997.
- 12 Hope KJ, Jin L and Dick JE: Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. *Nat Immunol* 5: 738-743, 2004.
- 13 Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB: Identification of human brain tumour initiating cells. *Nature* 432: 396-401, 2004.
- 14 Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD and Eberwine JH: Amplified RNA synthesized from limited quantities of heterogeneous cDNA. *Proc Natl Acad Sci USA* 87: 1663-1667, 1990.

- 15 Oshima Y, Ueda M, Yamashita Y, Choi YL, Ota J, Ueno S, Ohki R, Koinuma K, Wada T, Ozawa K, Fujimura A and Mano H: DNA microarray analysis of hematopoietic stem cell-like fractions from individuals with the M2 subtype of acute myeloid leukemia. *Leukemia* 17: 1990-1997, 2003.
- 16 Fellenberg K, Hauser NC, Brors B, Neutzner A, Hoheisel JD and Vingron M: Correspondence analysis applied to microarray data. *Proc Natl Acad Sci USA* 98: 10781-10786, 2001.
- 17 Alon U, Barkai N, Notterman DA, Gish K, Ybarra S, Mack D and Levine AJ: Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. *Proc Natl Acad Sci USA* 96: 6745-6750, 1999.
- 18 Ichikawa N, Kitano K, Ito T, Nakazawa T, Shimodaira S, Ishida F and Kiyosawa K: Abnormal proliferation of CD4-CD8+  $\gamma$ delta+ T cells with chromosome 6 anomaly: role of Fas ligand expression in spontaneous regression of the cells. *Am J Hematol* 60: 305-308, 1999.
- 19 Valk PJ, Verhaak RG, Beijten MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Lowenberg B and Delwel R: Prognostically useful gene-expression profiles in acute myeloid leukemia. *N Engl J Med* 350: 1617-1628, 2004.
- 20 Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, Rees JK, Stevens RF and Walker H: A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. *Br J Haematol* 107: 69-79, 1999.
- 21 Cox DR: Regression models and life tables. *J R Stat Soc* 34: 187-220, 1972.
- 22 Beer-DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB and Hanash S: Gene-expression profiles predict survival of patients with lung adenocarcinoma. *Nat Med* 8: 816-824, 2002.
- 23 Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JL, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO and Staudt LM: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature* 403: 503-511, 2000.
- 24 Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T and Staudt LM: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. *N Engl J Med* 346: 1937-1947, 2002.
- 25 Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster JC and Golub TR: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. *Nat Med* 8: 68-74, 2002.
- 26 Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, Behm FG, Pui CH, Downing JR, Gilliland DG, Lander ES, Golub TR and Look AT: Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. *Cancer Cell* 1: 75-87, 2002.
- 27 Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Relling MV, Patel A, Cheng C, Campana D, Wilkins D, Zhou X, Li J, Liu H, Pui CH, Evans WE, Naeve C, Wong L and Downing JR: Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. *Cancer Cell* 1: 133-143, 2002.
- 28 Kapp U, Yeh WC, Patterson B, Elia AJ, Kagi D, Ho A, Hessel A, Tipsword M, Williams A, Mirtsos C, Itie A, Moyle M and Mak TW: Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. *J Exp Med* 189: 1939-1946, 1999.
- 29 Skinnider BF, Elia AJ, Gascoyne RD, Trumper LH, von Bonin F, Kapp U, Patterson B, Snow BE and Mak TW: Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. *Blood* 97: 250-255, 2001.
- 30 Cavdar Koc E, Burkhart W, Blackburn K, Moseley A and Spremulli LL: The small subunit of the mammalian mitochondrial ribosome. Identification of the full complement of ribosomal proteins present. *J Biol Chem* 276: 19363-19374, 2001.
- 31 Bruyns E, Marie-Cardine A, Kirchgessner H, Sagolla K, Shevchenko A, Mann M, Autschbach F, Bensussan A, Meuer S and Schraven B: T cell receptor (TCR) interacting molecule (TRIM), a novel disulfide-linked dimer associated with the TCR-CD3-zeta complex, recruits intracellular signaling proteins to the plasma membrane. *J Exp Med* 188: 561-575, 1998.
- 32 Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R, Dohner H and Pollack JR: Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. *N Engl J Med* 350: 1605-1616, 2004.
- 33 Shim WS, Teh M, Bapna A, Kim I, Koh GY, Mack PO and Ger R: Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. *Exp Cell Res* 279: 299-309, 2002.
- 34 Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C, Bonomini S, Lunghi P, Hojden M, Genestreti G, Svaldi M, Coser P, Fattori PP, Sammarelli G, Gazzola GC, Bataille R, Almici C, Caramatti C, Mangoni L and Rizzoli V: Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. *Blood* 102: 638-645, 2003.

Received April 1, 2006  
Accepted May 15, 2006

# Signals from intra-abdominal fat modulate insulin and leptin sensitivity through different mechanisms: Neuronal involvement in food-intake regulation

Tetsuya Yamada,<sup>1,7</sup> Hideki Katagiri,<sup>2,7,\*</sup> Yasushi Ishigaki,<sup>1,7</sup> Takehide Ogihara,<sup>2</sup> Junta Imai,<sup>1,2</sup> Kenji Uno,<sup>1,2</sup> Yutaka Hasegawa,<sup>1,2</sup> Junhong Gao,<sup>1,2</sup> Hisamitsu Ishihara,<sup>1</sup> Akira Nijima,<sup>3</sup> Hiroyuki Mano,<sup>4</sup> Hiroyuki Aburatani,<sup>5</sup> Tomoichiro Asano,<sup>6</sup> and Yoshitomo Oka<sup>1</sup>

<sup>1</sup> Division of Molecular Metabolism and Diabetes

<sup>2</sup> Division of Advanced Therapeutics for Metabolic Diseases, Center for Translational and Advanced Animal Research Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan

<sup>3</sup> Niigata University School of Medicine, Niigata 951-8150, Japan

<sup>4</sup> Division of Functional Genomics, Jichi Medical School, Kawachi-gun, Tochigi 329-0498, Japan

<sup>5</sup> Research Center for Advanced Science and Technology, University of Tokyo, Tokyo 153-8904, Japan

<sup>6</sup> Department of Physiological Chemistry and Metabolism, University of Tokyo, Tokyo 113-8655, Japan

<sup>7</sup> These authors contributed equally to this work.

\*Correspondence: katagiri-ky@umin.ac.jp

## Summary

**Intra-abdominal fat accumulation is involved in development of the metabolic syndrome, which is associated with insulin and leptin resistance. We show here that ectopic expression of very low levels of uncoupling protein 1 (UCP1) in epididymal fat (Epi) reverses both insulin and leptin resistance. UCP1 expression in Epi improved glucose tolerance and decreased food intake in both diet-induced and genetically obese mouse models. In contrast, UCP1 expression in Epi of leptin-receptor mutant mice did not alter food intake, though it significantly decreased blood glucose and insulin levels. Thus, hypophagia induction requires a leptin signal, while the improved insulin sensitivity appears to be leptin independent. In wild-type mice, local-nerve dissection in the epididymis or pharmacological afferent blockade blunted the decrease in food intake, suggesting that afferent-nerve signals from intra-abdominal fat tissue regulate food intake by modulating hypothalamic leptin sensitivity. These novel signals are potential therapeutic targets for the metabolic syndrome.**

## Introduction


The explosive increase in obesity has become a major public health concern in most industrialized countries (Flier, 2004; Friedman, 2003). Insulin resistance is a fundamental contributor to the metabolic syndrome associated with type 2 diabetes, hypertension, hyperlipidemia, and atherosclerosis. Major advancements in this field include the discoveries of adipocyte-derived humoral factors, such as leptin (Friedman and Halaas, 1998). Leptin conveys energy-storage information from adipose tissue to the central nervous system, leading to food-intake suppression. However, in patients with ordinary obesity, serum leptin levels are increased in proportion to body fat (Considine et al., 1996), but the responses to leptin are impaired (Heymsfield et al., 1999), which defines a state of leptin resistance. Leptin resistance also contributes to the development of obesity and obesity-related metabolic disorders.

Fat accumulation in intra-abdominal fat tissue is involved in development of the metabolic syndrome (Bjorntorp, 1992; Matsuzawa et al., 1995) associated with insulin and leptin resistance (Friedman, 2003). Therefore, in this study, to examine whether the metabolic changes in intra-abdominal fat tissue affect insulin and leptin resistance as well as systemic glucose metabolism, we attempted to express uncoupling protein 1 (UCP1), which functions to dissipate energy as heat (Kling-

berg and Huang, 1999), in epididymal fat tissue (Epi) in mice with obesity and diabetes.

## Results and discussion

C57BL/6 mice were subjected to direct injection of the UCP1 adenovirus vector into Epi (UCP1 mice) after the development of diabetes associated with obesity in response to high-fat chow preloading for 4 weeks. Mice given the LacZ adenovirus were used as controls (LacZ mice). Immunoblotting detected adenovirus-mediated UCP1 expression in Epi (see Figure S1A in the Supplemental Data available with this article online), and this expression was restricted to Epi (Fig. S1A). UCP1 expression in Epi was detectable on the first day after adenoviral injection and was increased on day 3 but had fallen to very low levels by day 7 (Figure S1B). However, expression levels were far below those of endogenous protein in BAT: on day 3, approximately 5% per unit weight protein (Figure S1B). UCP1 expression was restricted to very limited portions of the tissue (left panel of Figure 1B). Judging from the intensity of immunostaining, UCP1 expression levels in UCP1-expressing white adipocytes did not reach those in brown adipocytes (right panel of Figure 1B). UCP1-expressing adipocytes were significantly smaller than UCP1-nonexpressing adipocytes in the same tissue (Figure 1C), suggesting enhanced metabolism in the former.



**Figure 1.** UCP1 expression in Epi improved glucose tolerance and insulin sensitivity

**A)** Immunoblotting, with anti-UCP1 antibody, of Epi extracts from LacZ and UCP1 mice on day 3 after adenoviral administration.

**B)** Immunohistochemistry, with anti-UCP1 antibody, of Epi (left panel) and BAT (right panel) sections from a UCP1 mouse on day 3 after adenoviral administration. These two samples were immunostained under the same conditions.

**C)** Diameters of UCP1-nonexpressing (gray bar) and UCP1-expressing (hatched bar) adipocytes in Epi from UCP1 mice on day 3 after adenoviral administration.

**D–J)** Epididymal fat weights (**D**), body weights (**E**), resting oxygen consumption during light and dark phase (**F**), and metabolic parameters (**G–J**) of LacZ mice (black bars) and UCP1 mice (white bars) on day 3 after adenoviral administration. Glucose-tolerance (**G**) and insulin-tolerance tests (**H**) were performed on day 3. Data in (**H**) are expressed as percentages of the blood glucose levels immediately before intraperitoneal insulin loading. Serum insulin levels (**I**) and serum lipid parameters (**J**; left: total cholesterol, middle: triglyceride, right: free fatty acids) were measured after a 10 hr fast ( $n = 6$  per group). Data are presented as means  $\pm$  SD ( $n = 6$  per group). \* $p < 0.05$  by unpaired  $t$  test.


We further confirmed enhanced metabolism by adenoviral UCP1 expression using 3T3-L1 adipocytes. UCP1 expression decreased intracellular ATP concentrations (Figure S1C) and increased levels of peroxisome proliferator-activated receptor  $\gamma$  coactivator (PGC)  $1\alpha$  and cytochrome  $c$  expression (Figure S1D). Thus, exogenous UCP1 was functionally active, resulting in increased mitochondrial biosynthesis in adipocytes.

However, neither total Epi weights nor body weights differed between LacZ and UCP1 mice on day 3 after adenoviral administration (Figures 1D and 1E). Oxygen consumption was not affected by UCP1 expression in Epi during either the light or the dark phase (Figure 1F), also reflecting the very limited UCP1 expression. Therefore, to avoid the secondary effects of body-weight change, we analyzed metabolic parameters on day 3. To our surprise, however, even very limited UCP1 expression in Epi resulted in marked changes in metabolic phenotype.

Glucose- and insulin-tolerance tests indicated marked improvements in glucose tolerance and insulin sensitivity (Figures 1G and 1H). Fasting blood glucose (Figure 1G) and insulin (Figure 1I) levels were significantly lower in UCP1 mice, further confirming improved insulin sensitivity. In addition, serum lipid parameters, including triglycerides and free fatty acids (Figure 1J), were also improved with UCP1 expression in Epi. Thus, limited regional expression of UCP1 in Epi markedly improved systemic insulin resistance, resulting in improvement of diabetes and dyslipidemia.

Next, we measured serum adipocytokine levels (Figure 2A). Adiponectin and tumor necrosis factor  $\alpha$  levels were not significantly altered. In contrast, serum leptin was markedly decreased, by 46%, with UCP1 expression in Epi. Although intra-abdominal fat-tissue weights were unaltered or only very slightly decreased in UCP1 mice (Figure 1D and Figure S1E),





**Figure 2.** UCP1 expression in Epi improved leptin sensitivity

**A–F)** LacZ (black bars) or UCP1 (white bars) adenovirus was injected into Epi of mice with dietary obesity.

**A)** Serum adipocytokine levels (left: adiponectin, middle: TNF $\alpha$ , right: leptin) in LacZ mice and UCP1 mice after a 10 hr fast on day 3 after adenoviral administration.

**B)** Relative amounts of leptin mRNA in adipose tissues.

**C)** Total food intakes on days 2 and 3 after adenoviral administration.

**D)** Relative amounts of neuropeptide Y (left) and proopiomelanocortin (right) mRNA were measured by quantitative RT-PCR using total RNA obtained from the hypothalamus on day 2 after adenoviral administration. Data were corrected with  $\beta$ -actin as the standard (**B** and **D**).

**E and F)** Leptin-tolerance tests were performed on day 3 after adenoviral administration. Data were expressed as ratios to the food intakes of vehicle-treated mice (**E**). Mice were weighed at 12 hr after each daily injection of leptin or vehicle (**F**).

**G–K)** LacZ (black bars) or UCP1 (white bars) adenovirus was injected into Epi of db/db mice.

**G)** Total food intakes on days 2 and 3 after adenoviral administration are presented.

**H–K)** Blood leptin (**H**), glucose (**I**), and insulin (**J**) levels and serum lipid parameters (**K**; left: triglyceride, right: free fatty acids) of db/db mice were measured after a 10 hr fast. Data are presented as means  $\pm$  SD ( $n = 8$  per group). \* $p < 0.05$ ; \*\* $p < 0.01$  by unpaired  $t$  test.

leptin mRNA expression was markedly decreased in intra-abdominal fat tissues (Figure 2B). Thus, the effects of UCP1 expression in Epi are also exerted in fat tissues other than those injected with the adenovirus. Food intake was significantly suppressed (Figure 2C), indicating that hypothalamic leptin sensitivity was markedly improved despite the lack of significant changes in body weights. Decreased leptin expression in several adipose tissues suggests efferent sympathetic nerve activation, which also supports leptin signal enhancement.

Administration of green fluorescent protein-adenovirus exerted minimal metabolic effects (Figures S1F–S1J). On day 7, when adenoviral UCP1 expression was markedly decreased (Figure S1B), blood glucose, insulin, and leptin levels did not differ between the UCP1 and LacZ mice (Figure S2). In addition, we confirmed the metabolic effects of UCP1 expression in Epi using three other obese models: AKR mice on high-fat chow and KK mice and KK-Ay mice on normal chow. In these three models, similar metabolic impacts were observed with UCP1 adenovirus

administration into Epi (Figure S3). Thus, UCP1 expression in Epi exerts acute, beneficial metabolic effects in both diet-induced and genetically obese models.

Increased leptin signals in the hypothalamus induced by UCP1 expression in Epi were further confirmed by changed levels of hypothalamic neuropeptide expression in UCP1 mice on day 3 after adenoviral administration. Real-time RT-PCR revealed adipose UCP1 expression to significantly decrease expression of neuropeptide Y, an orexigenic neuropeptide, while tending to increase that of proopiomelanocortin, a precursor of an anorexigenic neuropeptide, in the hypothalamus (Figure 2D).

To directly test whether leptin sensitivity was improved, we performed leptin-tolerance tests. When leptin was injected intraperitoneally into fasting mice on day 3, leptin-induced food-intake inhibition was far more profound in UCP1 mice than in LacZ mice (Figure 2E). In addition, when leptin was given daily, body weights were significantly decreased (Figure 2F). Thus,

even very limited UCP1 expression in Epi exerts a remote therapeutic effect on hypothalamic leptin resistance, which had already developed in response to preloading with high-fat chow. Transgenic overexpression of UCP1 (Kopecky et al., 1995) and rather minor induction of UCP1 in white adipose tissue (Cederberg et al., 2001; Leonardsson et al., 2004; Tsukiyama-Kohara et al., 2001; Um et al., 2004) result in resistance to high-fat-diet-induced obesity but do not reportedly cause hypophagia. In this study, however, we expressed UCP1 after the development of obesity and leptin resistance and were thus able to observe acute, beneficial effects, i.e., improved leptin sensitivity, which would be difficult to detect using congenitally UCP1-overexpressing mice.

Increased leptin sensitivity is likely to be involved in the phenotype of UCP1 mice. If this is the case, at least some of the phenotypic features of UCP1 mice would presumably be absent in mice lacking the hypothalamic leptin signal. To test this, UCP1 or LacZ adenovirus was injected into Epi of db/db mice, leptin-receptor Ob-Rb mutants. Food intake (Figure 2G) and serum leptin (Figure 2H) did not differ between LacZ-expressing and UCP1-expressing db/db mice. These findings confirm that the effect of UCP1 expression in Epi on food intake is leptin-signal dependent. On the other hand, UCP1 expression in Epi of db/db mice caused small but significant decreases in blood glucose (Figure 2I), insulin (Figure 2J), and triglyceride (Figure 2K) levels, as well as tending to decrease serum free-fatty-acid levels (Figure 2K). These findings demonstrate that UCP1 expression in Epi improves insulin sensitivity, in part, independently of leptin signaling.

To eliminate the secondary effects of reduced food intake, pair-feeding experiments were performed using C57BL/6 wild-type mice (Figure S4). Pair feeding did not significantly alter the body weights of LacZ mice. Fasting blood glucose did not differ between UCP1 mice and pair-fed LacZ mice, but after glucose loading, blood glucose levels were significantly lower in UCP1 mice. In addition, serum insulin and leptin levels were significantly lower in UCP1 mice than in pair-fed LacZ mice. Taken together with the results obtained using db/db mice, the improved insulin sensitivity induced by UCP1 expression in Epi appears not to be mediated solely by decreased food intake.


The same amounts of recombinant adenovirus encoding UCP1 were directly injected into subcutaneous fat tissues in the flank of C57BL/6 mice with dietary obesity and diabetes. UCP1 expression levels were similar to those obtained by injection into Epi (data not shown). Food intake was significantly decreased by UCP1 expression, as compared with LacZ expression, in subcutaneous fat (Figure 3A), but the effects were much smaller than those produced by UCP1 expression in Epi (Figure 2C). Furthermore, there were no statistically significant decreases in blood glucose (Figure 3B), insulin (Figure 3C), or leptin (Figure 3D) levels. Thus, exogenous UCP1 expression in subcutaneous fat was far less effective in improving insulin and leptin resistance than that in intra-abdominal fat tissue. These findings suggest the anatomical location of the manipulated adipose tissue to be involved in the observed therapeutic effects, which would appear to be important for understanding the metabolic differences between visceral fat-dominant and subcutaneous fat-dominant obesity.

How does the signal (or signals) from intra-abdominal fat tissue exert these remote effects? The importance of anatomical fat-tissue location suggests the involvement of neuronal signal-

ing. The afferent activity from Epi is reportedly transmitted through the nerve bundle, which runs alongside blood vessels supplying Epi, in rats (Nijijima, 1998). To study the possible involvement of neuronal signals from Epi, we dissected this nerve bundle in mice with dietary obesity and diabetes. Ten days after bilateral nerve-bundle dissection, adenoviruses were injected into Epi. No significant differences in body weights or Epi weights were observed between sham-operated and nerve-dissected mice (data not shown). While UCP1 adenoviral administration significantly decreased food intake in sham-operated mice, nerve dissection blunted this decrease in food intake such that it was no longer statistically significant (Figure 3E). Similarly, nerve dissection blunted a decrease in hypothalamic NPY mRNA expression, rendering it statistically insignificant (NPY; LacZ versus UCP1:  $12.06 \pm 6.16$  versus  $6.39 \pm 3.10$ ;  $p = 0.15$ ). These findings suggest that neuronal signals from intra-abdominal fat tissue are involved in food-intake regulation. In contrast, in nerve-dissected mice, blood glucose (Figure 3F) as well as serum insulin (Figure 3G) and leptin (Figure 3H) levels were significantly suppressed in a fashion similar to in sham-operated mice. Thus, improved insulin resistance is largely independent of this neuronal pathway.

To confirm that afferent-nerve signals are involved in UCP1-expression-mediated suppression of food intake, we next examined the effects of functional deafferentation by administering capsaicin (Fu et al., 2003), a selective neurotoxin for unmyelinated C fibers. In LacZ mice, food intake was not altered by capsaicin treatment 10 days prior to adenoviral administration. In contrast, capsaicin pretreatment significantly reversed the food-intake suppression induced by UCP1 expression in Epi (Figure 3I). The inhibitory effect of capsaicin pretreatment was very similar to that of local-nerve dissection (Figure 3E). Taken together, these observations suggest that afferent-nerve signals from Epi are involved in food-intake regulation. To elucidate the molecular mechanism whereby UCP1 expression in Epi modulates neuronal activity, we searched for genes upregulated by adipose UCP1 expression. Using the DNA microarray technique, gene expressions were examined in LacZ- and UCP1-adenovirus-treated Epi (Table S1) and in 3T3-L1 adipocytes (Table S2). With the exception of UCP1, however, there was no overlap in genes showing significantly increased expression. Although further expression profiling including proteomic approaches might elucidate the underlying mechanisms, the apparent lack of genes showing increased expression raises the possibility that the activation of afferent nerves does not involve gene-expression alterations. For instance, UCP1 generates heat, and a capsaicin receptor, TRPV1, is activated by a slightly above normal body temperature (Caterina et al., 1997). Capsaicin treatment affected UCP1-induced food-intake suppression (Figure 3I), raising the possibility that UCP1 expression activates capsaicin-sensitive nerves via TRPV1 activation. Another possibility is involvement of reactive oxygen species, which are affected by mitochondrial uncoupling (Bernal-Mizrachi et al., 2005; Jezek et al., 2004) and reportedly regulate capsaicin-sensitive afferent fibers (Ruan et al., 2005). Further studies are required to examine these hypotheses.

In this study, very limited UCP1 expression in Epi markedly improved insulin and leptin resistance, thereby improving glucose tolerance and decreasing food intake. UCP1 mice were more insulin sensitive than pair-fed LacZ mice. In addition, in db/db mice, despite no food-intake suppression, blood glucose



**Figure 3.** Neuronal signals are likely to be involved in food-intake regulation


**A–D)** LacZ (black bars) or UCP1 (white bars) adenovirus was injected into subcutaneous fat, and metabolic markers were measured. Total food intakes on days 2 and 3 after adenoviral administration are presented. Blood glucose (**B**), insulin (**C**), and leptin (**D**) levels were determined after a 10 hr fast on day 3 after adenoviral administration. \*\**p* < 0.01 by unpaired *t* test.

**E–H)** Mice were subjected to local-nerve dissection 10 days prior to adenoviral injection into Epi. Total food intakes of sham-operated (sham) and nerve-dissected (cut) mice (**E**) on days 2 and 3 are presented graphically. Blood glucose (**F**), serum insulin (**G**), and leptin (**H**) levels were determined on day 3. **I)** Mice were treated with capsaicin or vehicle 10 days prior to adenoviral injection into Epi. Total food intakes on days 2 and 3 after administration of LacZ (black bars) or UCP1 (white bars) adenovirus are presented. In (**E**) and (**I**), the food intakes of UCP1 mice are expressed in the right graph as ratios to those of LacZ mice. \*\**p* < 0.01 assessed by one-factor ANOVA. Data are presented as means ± SD.

and insulin levels were modestly but significantly decreased by UCP1 expression in Epi. Thus, the mechanism underlying improved insulin sensitivity with UCP1 expression in Epi is, in part, independent of leptin signaling and food-intake suppression (Figure 4). Dissection of the nerve bundle from Epi did not alter the decreases in blood glucose and insulin levels. Taken together with the findings that UCP1 expression in subcutaneous fat did not significantly decrease blood glucose or insulin levels, our observations indicate that nonneuronal signals including humoral factors from intra-abdominal adipose tissue possibly participate in systemic improvement of insulin resistance. Since UCP1 expression was observed in a very limited population of adipocytes in Epi, suppression of insulin-resistant adipocytokine secretion is unlikely to explain the beneficial effects. Serum adiponectin levels were not altered, suggesting involvement of other unknown insulin-sensitizing factor (or factors).

On the other hand, decreased food intake is likely to be, at least partially, mediated by afferent-nerve signals from Epi (Figure 4). Afferent-nerve signals from Epi to the central nervous

system reportedly result in a reflex from epididymal fat to white adipose tissues via efferent sympathetic-nerve activation (Nijima, 1998; Tanida et al., 2000). In addition, vagal afferent



**Figure 4.** The proposed mechanism whereby UCP1 expression in Epi decreases food intake and improves glucose tolerance

neuronal signals from intra-abdominal tissues, including the gut (Fu et al., 2003; Smith et al., 1981) and the liver (Friedman, 1998; Scharrer, 1999), are known to play a part in regulating food intake. We also reported that UCP1 gene administration into the liver modulates food intake (Ishigaki et al., 2005). Herein we report that intra-abdominal fat tissue is likely to convey metabolic signals to the brain via a neuronal pathway, in addition to via the circulation, resulting in modulation of food intake. Although the precise molecular mechanism remains to be elucidated, this neuronal pathway might play a role in development of the metabolic syndrome, making it a potentially novel therapeutic target.

## Experimental procedures

### Preparation of recombinant adenovirus

Recombinant adenovirus containing murine UCP1 cDNA (Ishigaki et al., 2005) was constructed as described previously (Katagiri et al., 1996). Recombinant adenoviruses bearing the bacterial  $\beta$ -galactosidase gene (*Adex1CALacZ*) and green fluorescent protein (*AdCMV-GFP*) were used as controls.

### Animals and in vivo adenovirus injection into fat pad

Animal studies were conducted in accordance with the institutional guidelines for animal experiments at Tohoku University. Male C57BL/6N and AKR/N mice were housed individually, and high-fat-chow feeding (32% safflower oil, 33.1% casein, 17.6% sucrose, and 5.6% cellulose) (Ishigaki et al., 2005) was initiated at 5 weeks of age. After 4 weeks of high-fat-chow loading, body-weight-matched mice were anesthetized prior to dissection of the skin and body wall. The adenoviral preparation ( $1 \times 10^9$  plaque-forming units in a volume of 20  $\mu$ l) was injected at two points each on each side of the epididymal fat pad or subcutaneous fat tissues in the flank, i.e., a total of four points. KK mice and KK-Ay mice maintained on a standard diet (65% carbohydrate, 4% fat, 24% protein) were similarly administered adenoviruses at 9 weeks and 5 weeks of age, respectively.

### Immunoblotting

Tissue protein extracts (250  $\mu$ g total protein) were boiled in Laemmli buffer containing 10 mM dithiothreitol, subjected to SDS-polyacrylamide gel electrophoresis, and transferred onto nitrocellulose filters. The filters were incubated with anti-UCP1 antibody (Santa Cruz Biotechnology, Santa Cruz, California) and then with anti-goat immunoglobulin G coupled to horseradish peroxidase. The immunoblots were visualized with an enhanced chemiluminescence detection kit (Amersham, Buckinghamshire, UK). The intensities of bands were quantified with the NIH Image 1.62 program.

### Histological analysis

Mouse epididymal fat and BAT were immunostained as previously reported (Ishigaki et al., 2005). Mature white adipocytes were identified by their characteristic unilocular appearance. Diameters of 100 or more white adipocytes per mouse in each group were traced manually and analyzed.

### Oxygen consumption

Oxygen consumption was measured as previously reported (Ishigaki et al., 2005).

### Pair-feeding experiments

Pair-feeding experiments were performed as previously described (Ishigaki et al., 2005).

### Blood analysis

Blood glucose and serum insulin, leptin, adiponectin, TNF $\alpha$ , total cholesterol, triglyceride, and free-fatty-acid levels were determined as previously described (Ishigaki et al., 2005).

### Measurement of quantitative RT-PCR-based gene expression

The skull was reflected from the brain and the hypothalamus was isolated by snap freezing in liquid nitrogen as previously reported (Bjorbaek et al., 1998).

Total RNA was isolated from mouse hypothalamus, fat tissues, or 3T3-L1 adipocytes with ISOGEN (Wako Pure Chemical Co., Osaka, Japan), and cDNA synthesized from total RNA was evaluated with a real-time PCR quantitative system (Light Cycler Quick System 350S; Roche Diagnostics GmbH, Mannheim, Germany). The relative amount of mRNA was calculated with  $\beta$ -actin mRNA as the invariant control. The primers used are shown in Table S3.

### Glucose-, insulin-, and leptin-tolerance tests

Glucose-tolerance tests were performed on fasted (10 hr, daytime) mice. Mice were given glucose (2 g/kg of body weight) intraperitoneally, followed by measurement of blood glucose levels. Insulin-tolerance tests were performed on ad libitum-fed mice. Mice were intraperitoneally injected with human regular insulin (0.75 U/kg of body weight; Eli Lilly Co., Kobe, Japan).

Leptin-tolerance tests were carried out as described in a previous report (Igel et al., 1997), with slight modification. Fasted (12 hr) mice were injected with mouse leptin (7.2 mg/kg of body weight; R&D Systems, Inc.) intraperitoneally, and food intakes were monitored for 12 hr after the injection. To examine effects on body-weight change, these two groups of mice were given leptin daily starting on the day of adenoviral administration. Each mouse was then weighed.

### Capsaicin treatments

Capsaicin treatment was performed as described in a previous report (Fu et al., 2003), with minor modification. Mice were anesthetized prior to subcutaneous injection of capsaicin solution (50 mg/kg, 12.5 mg/ml dissolved in vehicle). The control group received vehicle treatment (10% Tween 80, 10% ethanol, and 80% saline) under identical administration conditions. Adenoviral administration into Epi was carried out 10 days later.

### Local-nerve dissection

The small nerve bundle which runs along side blood vessels supplying Epi was dissected as previously reported (Nijijima, 1998). Ten days after bilateral dissection of this nerve bundle, adenoviruses were injected into epididymal fat pad.

### Measurement of ATP

Fully differentiated 3T3-L1 adipocytes were infected with recombinant adenoviruses as previously described (Katagiri et al., 1996). Intracellular ATP levels were measured using an ATP determination kit (TOYO B-Net, Tokyo, Japan).

### Microarray experiments

Total RNA from epididymal fat or 3T3-L1 adipocytes was used to synthesize cRNA, which was then hybridized to an HG-U133A oligonucleotide array (Affymetrix, Santa Clara, California) according to standard protocols, as described previously (Hippo et al., 2002).

### Statistical analysis

All data were expressed as means  $\pm$  SD. The statistical significance of differences was assessed by the unpaired t test and one-factor ANOVA.

### Supplemental data

Supplemental Data include four figures and three tables and can be found with this article online at <http://www.cellmetabolism.org/cgi/content/full/3/3/223/DC1/>.

### Acknowledgments

We appreciate Drs. L.P. Kozak (Pennington Biomedical Research Center) and H. Mizuguchi (National Institute of Biomedical Innovation) for the generous gifts of UCP1 cDNA and GFP-adenovirus, respectively. We thank Ms. H. Meguro (Tokyo University) for technical support. This work was supported by a Grant-in-Aid for Scientific Research (B2, 15390282) and a Grant-in-Aid for Exploratory Research (15659214) to H.K. from the Ministry of Education, Science, Sports and Culture of Japan and a Grant-in-Aid for Scientific Research (H16-genome-003) to Y.O. from the Ministry of Health, Labor and Welfare of Japan. This work was also supported by the 21st Century COE Programs "CRESCENDO" (H.K.) and "the Center for Innovative Therapeutic Development for Common Diseases" (Y.O.) of the Ministry of Education, Science, Sports and Culture.